Аn international, multicenter, non-interventional real-life clinical practice Register studying the Actual therapeutic patient population with Multifocal Atherosclerosis in the Russian Federation and Eurasian countries
Information on demographics, comorbidities, methods for diagnosing multifocal atherosclerosis (MFA), prescribed therapy, and outcomes will be identified via medical records analysis. Results of arterial bed ultrasound examination (US), results of ankle-brachial index (ABI) measurements, along with clinical and anamnestic data on target organ damage in the MFA-affected areas will be used as the main source verifying the presence MFA. The follow-up period for each patient will span from the date of inclusion and over the next year with an additional 6 and 12 months of follow-up. Patients eligible for entry in the Register must be included and their details must be documented. The procedure for obtaining informed consent for the examination and collection of data must comply with the requirements of local legislation. Patients will be required to sign an informed consent document if required. Standardized electronic CRFs will be used in all research centers. The electronic data collection (EDC) system must be validated in accordance with current standards and legal requirements. Researchers will log into this system using individually assigned usernames and passwords. Data can only be entered and corrected by the researcher or other authorized personnel of the research center.
Study Type
OBSERVATIONAL
Enrollment
3,059
Eurasian Association of Therapists
Moscow, Russia
Occurrence of a cardiovascular event (stroke, ACS, amputation, hospitalizations (related or not to cardiovascular pathology), the number of emergency calls)
To assess the occurrence of cardiovascular events in 6 and 12 months in a cohort of patients with MFA: brain hemorrhage, acute coronary syndrome, amputation, admission to hospital (related or not related to a cardiovascular disease), number of emergency calls
Time frame: after 12 months
All-cause mortality
To estimate overall mortality at 6 and 12 months in a cohort of patients with MFA
Time frame: after 12 months
The frequency of any bleeding episodes (life-threatening, bothersome, or of unknown severity)
To evaluate bleeding at 6 and 12 months in a cohort of patients with MFA
Time frame: after 12 months
Change of GFR according to Chronic Kidney Disease Epidemiology Collaboration
To compare the course of CKD in different subpopulations of patients
Time frame: after 12 months
Prevalence of risk factors in the population
To estimate the prevalence of risk factors in the population
Time frame: after 12 months
Change of 3 point major adverse cardiovascular events parameter (Cardiovascular death, Nonfatal stroke, Non-fatal myocardial infarction)
To evaluate patients according to 3P MACE parameter ((Cardiovascular death, Nonfatal stroke, Non-fatal myocardial infarction) according to prescribed therapy
Time frame: after 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.